个人简介
Paolo Ghia教授是CLL战略项目的主任,也是圣拉斐尔科学研究医院B细胞肿瘤研究科室的负责人。此外,他还是圣拉斐尔生命健康大学肿瘤内科的正教授。
在临床和研究领域,Ghia教授三十年来一直致力于开展肿瘤血液学的转化研究,尤其是惰性白血病/淋巴瘤(包括慢性淋巴细胞白血病[CLL])的转化研究。
Paolo Ghia教授是多个国际科学协会的成员,包括:
- GIMEMA(意大利成人恶性血液病组)淋巴细胞增生性疾病工作组共同主席、
- CLL国际研讨会(iwCLL)成员、
- GIMEMA(意大利成人恶性血液病组)淋巴细胞增生性疾病工作组成员、
- 欧洲CLL研究倡议(ERIC)主席、
- WHO淋巴细胞和组织细胞恶性肿瘤临床咨询委员会成员、
- Henry Kunkel学会(美国纽约)成员。
教育背景
都灵大学
1990年,医学博士学位
都灵大学
1996年,人类肿瘤领域博士研究生
都灵大学(Polo di Orbassano)
2003年,内科学专业学位
出版物
最新出版物
Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications.
Haematologica. 2017 Jun;102(6):1085-1090. doi: 10.3324/haematol.2016.157552. PMID: 28255015
扩展阅读
Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia.
Nat Commun. 2017 Jun 9;8:15746. doi: 10.1038/ncomms15746.
扩展阅读
Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations.
Haematologica. 2018 Feb 15. pii: haematol.2017.177212. doi: 10.3324/haematol.2017.177212.
扩展阅读
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
Haematologica. 2018 Apr 19. pii: haematol.2018.189837. doi: 10.3324/haematol.2018.189837. [Epub ahead of print]PMID: 29674504
扩展阅读
Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments.
Leukemia. 2018 Jun;32(6):1307-1316. doi: 10.1038/s41375-018-0109-x. Epub 2018 Mar 26. PMID: 29700386.
扩展阅读
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Haematologica. 2018 Jun 7. pii: haematol.2018.192328. doi: 10.3324/haematol.2018.192328. PMID: 29880603.
扩展阅读
A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia.
Oncotarget. 2018 May 25;9(40):26019-26031. doi: 10.18632/oncotarget.25419. eCollection 2018 May 25. PMID: 29899839.
扩展阅读
High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: Integrating molecular and cellular therapies.
Blood. 2018 Jul 11. pii: blood-2018-01-826008. doi: 10.1182/blood-2018-01-826008. PMID: 29997221.
扩展阅读
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.
Am J Hematol. 2018 Aug 20. doi: 10.1002/ajh.25259. PMID: 30129285.
扩展阅读
Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.
Leukemia. 2019 Jan 3. doi: 10.1038/s41375-018-0335-2. PMID: 30607020
扩展阅读